timothy sykes logo
CAPR Stock Craters As FDA Slams Deramiocel Data, Lawsuits Swirl Thumbnail
G Google News

CAPR Stock Craters As FDA Slams Deramiocel Data, Lawsuits Swirl

ELLIS HOBBS•UPDATED JUL. 30, 2026, 9:19 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Amid mixed biotech sentiment, Capricor Therapeutics Inc. faces mounting pressure as its stocks have been trading down by -50.38 percent.

Key Takeaways For CAPR Traders

  • FDA advisory committee briefing documents for Capricor’s lead cell therapy deramiocel for Duchenne-associated cardiomyopathy raised serious concerns about the effectiveness data, risk–benefit profile, and a post‑hoc change to the primary endpoint/statistical analysis plan.
  • Following release of the FDA briefing documents, Capricor Therapeutics’ shares plunged approximately 60–70%, with reports citing intraday drops of about 62–65% and trading around $7.00.
  • Multiple securities law firms, including Kehoe Law Firm, Block & Leviton, Rosen Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith, have launched or announced investigations into potential securities fraud or investor claims related to Capricor’s prior representations about deramiocel’s data and FDA review.
  • An analyst from Cantor Fitzgerald described the FDA briefing documents as painting an “ugly picture” and questioning data integrity, reinforcing investor concerns around regulatory and scientific risk for deramiocel.

Candlestick Chart

Live Update At 09:19:22 EDT: On Thursday, July 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending down by -50.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics Inc. (CAPR) just went from a steady biotech story to a full‑blown volatility play. On the daily chart, CAPR traded in the $18–$22 zone for weeks, closing at $19.70 on 2026/07/24. Then the FDA briefing documents on deramiocel dropped, and the floor gave out.

By 2026/07/27, CAPR closed at $6.995, a collapse of roughly two‑thirds from the prior week. The latest daily close near $6.57 shows the stock trying to stabilize but still stuck in the single digits. That’s textbook broken trend behavior — former support in the high teens is now distant overhead resistance.

Fundamentally, CAPR is a classic clinical‑stage biotech profile. The company is unprofitable, with deeply negative returns on equity and assets and pretax margins around -489%. Cash flow from operations is negative and free cash flow is also in the red, which is normal for a development‑stage name but matters now that sentiment has flipped.

More Breaking News

The balance sheet does offer one cushion. CAPR carries minimal debt and sports strong liquidity ratios, with a high current ratio and sizeable cash and short‑term investments. For traders, that means near‑term bankruptcy risk looks low, but dilution and headline risk stay front and center while the deramiocel story is under pressure.

Why Traders Are Watching CAPR’s FDA And Legal Fallout

CAPR is now a case study in how fast a biotech story can reverse when the FDA questions trial integrity. The advisory committee briefing documents on deramiocel didn’t just nitpick. They flagged serious concerns around effectiveness, the overall benefit–risk profile for this Duchenne‑associated cardiomyopathy therapy, and a post‑hoc change to the primary endpoint and statistical analysis plan.

For CAPR traders, that is exactly the type of language that kills approval odds in the near term. When regulators say the benefit–risk profile appears unfavorable and question data handling, the market assumes the path forward is long, expensive, and uncertain. The result: CAPR shares cascading 60–70% in a matter of sessions, with reports of intraday crashes of roughly 62–65% and trading near $7.00.

The damage is not only regulatory. Kehoe Law Firm, Block & Leviton, Rosen Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith have all announced securities investigations tied to how Capricor Therapeutics presented deramiocel data and the FDA review. Several law firms highlight the FDA’s statements that current evidence does not provide substantial proof of effectiveness and that trial‑design changes came after randomization.

That combination — FDA skepticism plus multiple class‑action shops circling — is exactly why an analyst at Cantor Fitzgerald said the briefing documents painted an “ugly picture” and raised data‑integrity questions. When Wall Street reads “ugly picture,” many funds simply step aside. For active CAPR traders, the setup becomes a battleground: heavy overhead supply, extreme headline risk, and the potential for violent bounces driven more by short‑covering than genuine confidence.

Conclusion

Right now, CAPR sits where very few traders are comfortable: between a harsh FDA critique and a wall of legal headlines. The stock’s meltdown from the high teens into the mid‑single digits reflects a market that no longer assigns much near‑term value to deramiocel. Until Capricor Therapeutics addresses the FDA’s concerns around trial methodology, benefit–risk, and those post‑hoc statistical changes, CAPR remains a sentiment‑driven ticker, not a clean fundamental swing.

At the same time, CAPR’s strong cash position and low leverage mean this is not a zero‑overnight story. The company still has resources to respond to regulators and defend itself as securities‑law investigations progress. But for traders, that simply means the timeline stretches out. Regulatory and litigation overhangs often drag on for months or years, creating spikes and fades rather than smooth trends.

This is where discipline matters. In the words of Tim Sykes, “Volatility is an opportunity only for traders who respect risk, cut losses fast, and never fall in love with a story.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. CAPR now fits that description perfectly — a beaten‑down biotech where every new FDA comment or law‑firm update can move the tape. For educational and research purposes, traders studying CAPR should treat it as a live lesson in headline risk, liquidity, and the power of strict trading rules.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”